NewEdge Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

NewEdge Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$111K	–	432
2017 Q3	$111K	Hold	10,000	–	–	0.02%	369
2017 Q2	$109K	Hold	10,000	–	–	0.02%	400
2017 Q1	$98K	Hold	10,000	–	–	0.02%	266
2016 Q4	$103K	Hold	10,000	–	–	0.03%	253
2016 Q3	$102K	Buy	+10,000	New	+$109K	0.03%	213

NewEdge Advisors's SCLN Position: Q4 2017 in Review

NewEdge Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 10,000 shares — an estimated $111K sold.

NewEdge Advisors first reported a position in SCLN in Q3 2016 and held it in 5 quarters. The position peaked at $111K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

NewEdge Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
NewEdge Advisors sold 10,000 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $111K.
NewEdge Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q3 2016 and held it in 5 quarters.
NewEdge Advisors's Sciclone Pharmaceuticals Inc position peaked at $111K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on NewEdge Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.